Delayed oral toxicity from long‐term vemurafenib therapy | Zendy

LloydLavery A. | Zendy; Hodgson T. | Zendy; Coupe N. | Zendy; Bond S. | Zendy; Shah K. | Zendy; Espinosa O. | Zendy; Payne M.J. | Zendy; Middleton M.R. | Zendy; Matin R.N. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Delayed oral toxicity from long‐term vemurafenib therapy

Author(s) -

LloydLavery A.,

Hodgson T.,

Coupe N.,

Bond S.,

Shah K.,

Espinosa O.,

Payne M.J.,

Middleton M.R.,

Matin R.N.

Publication year - 2016

Publication title -

british journal of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.304

H-Index - 179

eISSN - 1365-2133

pISSN - 0007-0963

DOI - 10.1111/bjd.14457

Subject(s) - medicine , vemurafenib , toxicity , asymptomatic , lesion , basal cell , dermatology , oncology , gastroenterology , surgery , cancer , metastatic melanoma

We read with interest the article by Vigarios et al.1 describing eight patients treated with a variety of BRAF inhibitors who developed asymptomatic hyperkeratotic oral mucosal lesions. These were frequently multifocal and presented following a mean onset of three months of treatment with a BRAF inhibitor. In one patient, one such lesion rapidly developed into oral squamous cell carcinoma requiring excision. We would like to highlight delayed oral toxicity in a long-term responder to a BRAF inhibitor.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research